![Asceneuron has secured USD 100 million in Series C funding to advance its mission of developing OGA inhibitors for neurodegenerative diseases like Alzheimer's.](https://ggba.swiss/app/uploads/2024/07/Asceneuron-Alzheimer-2360x1622-1-1024x704.jpeg)
Powering innovation with an interdisciplinary network
22 February 2022
![](https://ggba.swiss/app/uploads/2023/06/RET-sitem-insel-Bldg-OpenDoor-B008-0028-copyright-sitem-insel-AG-1.jpg)
Opportunities for Nordic healthcare companies in Switzerland
The Greater Geneva Bern area (GGBa), the Swedish Swiss Chamber of Commerce and the Nordic Chambers in Switzerland, in collaboration with regional chambers and trade organisations in the Nordics, have the pleasure of inviting you to a webinar with sitem-insel on “Powering innovation with an interdisciplinary network – Opportunities for Nordic healthcare companies in Switzerland”.
sitem-insel is the Swiss Institute for Translational and Entrepreneurial Medicine based on the Insel campus in Bern, next to one of the largest university hospitals and medical faculties in Switzerland. sitem-insel is a catalyst for a multidisciplinary collaborative approach to unlocking “bench to bedside” innovation. It brings academia, government, industry, and science together in one place, with one goal: operational excellence in translational research.
Find out more about collaboration opportunities for Nordic start-ups and SMEs with our speakers Henri Troillet, Director of Germany & Nordics at GGBa, Vassiliki Riesen, Senior Project Manager at Bern Economic Development Agency, Dr. Julie Risse, Chief Business Officer at sitem-insel, and Dr. Nina Hobi, CEO & Scientific Director at AlveoliX.